Ovarian Cancer-Associated KPCG Variant Analysis

Abstract

Ovarian cancer is the most common cause of death from gynaecologic cancers, accounting for 4% of all cancers in women. The early-stage ovarian cancer is frequently about 75 percent of women with the disease are diagnosed with advanced disease. Ovarian cancer is when diagnosed in late stages, exhibits chemotherapy resistance; thus, there is a need to identify new targets that can aid in the early prognosis of ovarian cancer. Many SNPs in genes such as BRCA1, BRCA2, and TP53 have been linked to ovarian cancer. KPCG belongs to the KPC family, a large family of serine-threonine kinases. KPC gamma, a member of the conventional KPC family, has been implicated in a variety of cancers, but the protein has received little attention in the context of single nucleotide polymorphism. The purpose of this study is to see if single nucleotide polymorphisms (SNPs) in the PRKCG gene affect ovarian cancer susceptibility and prognosis. The SNPs in KPC gamma affect both the protein structure and function, as well as its protein-protein interactions. There was a positive association between KPC variant ID rs1331232028 (AA) with ovarian cancer, but no association between KPC variant ID rs923331350 with ovarian cancer was found. As a result, the findings suggest that KPC variant ID rs1331232028 could be used as a prognostic biomarker in ovarian cancer.